Beta-blocking effect of propafenone based on spectral analysis of heart rate variability.

RR variability was analyzed in 15 patients with ventricular arrhythmias to evaluate whether the antiarrhythmic action of propafenone is associated with alteration of neural control mechanisms. Before drug administration, spectral analysis of RR variability was characterized by 2 major components at low and high frequency, which are considered to reflect sympathetic and parasympathetic modulation of the heart period. After propafenone (600 to 900 mg/day), there was a marked reduction in RR variance (826 +/- 184 to 412 +/- 77 ms2; p < 0.05), although the mean RR interval was unchanged. The drug significantly reduced the low-frequency component (52 +/- 6 to 28 +/- 4 nu) and augmented the high-frequency component (39 +/- 6 to 55 +/- 5 nu). As a result, the low-/high-frequency ratio (an index of sympathovagal balance) decreased from 2.0 +/- 0.4 to 0.6 +/- 0.1. A positive correlation between serum levels and drug-induced changes in the low-frequency component was also observed. Furthermore, the increase in the low-frequency component induced by tilt (53 +/- 5 to 79 +/- 3 nu) was markedly attenuated after drug administration (27 +/- 5 to 54 +/- 7 nu). Thus, propafenone administration is associated with changes in spectral components that are consistent with a beta-blocking effect of the drug.

[1]  Lippincott Williams Wilkins,et al.  The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. , 1991, Circulation.

[2]  H. Huikuri,et al.  Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol. , 1989, Circulation.

[3]  A. Malliani,et al.  Cardiovascular Neural Regulation Explored in the Frequency Domain , 1991, Circulation.

[4]  D. Roden,et al.  Drug therapy : propafenone , 1990 .

[5]  R J Cohen,et al.  Assessment of autonomic regulation in chronic congestive heart failure by heart rate spectral analysis. , 1988, The American journal of cardiology.

[6]  B. Lown,et al.  Sudden cardiac death: the major challenge confronting contemporary cardiology. , 1979, The American journal of cardiology.

[7]  J. Fleiss,et al.  Risk stratification and survival after myocardial infarction. , 1983, The New England journal of medicine.

[8]  B Lown,et al.  Neural activity and ventricular fibrillation. , 1976, The New England journal of medicine.

[9]  R. Cohen,et al.  Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. , 1981, Science.

[10]  G. Stiles,et al.  Demonstration of beta adrenoceptor blockade by propafenone hydrochloride: clinical pharmacologic, radioligand binding and adenylate cyclase activation studies. , 1984, The Journal of pharmacology and experimental therapeutics.

[11]  P. Schwartz.  Neural mechanisms in cardiac arrhythmias , 1978 .

[12]  R J Cohen,et al.  Power spectrum analysis of heart rate variability in human cardiac transplant recipients. , 1989, Circulation.

[13]  M. Turiel,et al.  Power Spectral Analysis of Heart Rate and Arterial Pressure Variabilities as a Marker of Sympatho‐Vagal Interaction in Man and Conscious Dog , 1986, Circulation research.

[14]  J. Miller,et al.  Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. , 1987, The American journal of cardiology.

[15]  A J Camm,et al.  Baroreflex sensitivity and electrophysiological correlates in patients after acute myocardial infarction. , 1991, Circulation.

[16]  A J Camm,et al.  Prognostic value of reduced heart rate variability after myocardial infarction: clinical evaluation of a new analysis method. , 1991, British heart journal.

[17]  E. Benfenati,et al.  High-performance liquid chromatographic separation and mass spectrometric identification of propafenone, 5-hydroxypropafenone and N-depropylpropafenone. , 1988, Journal of Chromatography A.

[18]  A. Malliani,et al.  Continuous 24-hour assessment of the neural regulation of systemic arterial pressure and RR variabilities in ambulant subjects. , 1990, Circulation.

[19]  J P Miller,et al.  The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. , 1984, Circulation.

[20]  L. Horowitz,et al.  Many things are not found in books or journals ... but some things are! Value of electrophysiologic testing in patients with malignant ventricular arrhythmias. , 1988, The American journal of cardiology.

[21]  W. Rogers,et al.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.

[22]  J. Fleiss,et al.  Effect of atenolol and diltiazem on heart period variability in normal persons. , 1991, Journal of the American College of Cardiology.

[23]  A Malliani,et al.  Neural mechanisms in life-threatening arrhythmias. , 1980, American heart journal.

[24]  F. Lombardi,et al.  Relationship between sympathetic neural activity, coronary dynamics, and vulnerability to ventricular fibrillation during myocardial ischemia and reperfusion. , 1983, American heart journal.

[25]  D. Adam,et al.  Assessment of autonomic function in humans by heart rate spectral analysis. , 1985, The American journal of physiology.

[26]  Peter J. Schwartz,et al.  Heart rate variability in patients with ventricular arrhythmias: Effect of antiarrhythmic drugs , 1991 .

[27]  R. Candinas,et al.  Role of the sympathetic nervous system in the genesis of ventricular arrhythmia. , 1990, Circulation.

[28]  W. Craelius,et al.  Use of heart rate spectral analysis to study the effects of calcium channel blockers on sympathetic activity after myocardial infarction. , 1990, American heart journal.

[29]  A Malliani,et al.  Circadian variation of spectral indices of heart rate variability after myocardial infarction. , 1992, American heart journal.

[30]  P. Schwartz,et al.  Baroreflex sensitivity, clinical correlates, and cardiovascular mortality among patients with a first myocardial infarction. A prospective study. , 1988, Circulation.

[31]  D. Roden,et al.  The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. , 1990, The New England journal of medicine.

[32]  R. Carney,et al.  Correlation of heart rate variability with clinical and angiographic variables and late mortality after coronary angiography. , 1988, The American journal of cardiology.

[33]  S Cerutti,et al.  Heart rate variability as an index of sympathovagal interaction after acute myocardial infarction. , 1987, The American journal of cardiology.